Glaxo Avandia Sales Appear To Be Vanishing (GSK)
GlaxoSmithKline's (NYSE:GSK) Avandia sales might not just weak after the reports of cardiovascular risks were reported. If this research is accurate, the sales might be on the path to vanishing. ...Read Full Story »

